Thomas Sciascia

CIK: 0001229946

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TRVI

Trevi Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

TRVI
Trevi Therapeutics, Inc.
Feb 19, 2026
Award(A)
Stock Option (right to buy)
Direct
85K shares-
TRVI
Trevi Therapeutics, Inc.
May 31, 2025
Award(A)
Performance Stock Option (right to buy)
Direct
60K shares-
TRVI
Trevi Therapeutics, Inc.
Mar 25, 2025
Exercise(M)
Direct
2.6K shares at avg. $1.43$4K
TRVI
Trevi Therapeutics, Inc.
Mar 25, 2025
Sale(S)
Direct
2.6K shares at avg. $6.60$17K
TRVI
Trevi Therapeutics, Inc.
Mar 10, 2025
Award(A)
Performance Stock Option (right to buy)
Direct
32K shares-
TRVI
Trevi Therapeutics, Inc.
Feb 18, 2025
Award(A)
Stock Option (right to buy)
Direct
116K shares-

		Type	Shares	Price		Ownership
Feb 19, 2026	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	85,000	-	-	Direct
May 31, 2025	TRVI Trevi Therapeutics, Inc.	Award(A) Performance Stock Option (right to buy)	60,000	-	-	Direct
Mar 25, 2025	TRVI Trevi Therapeutics, Inc.	Exercise(M)	2,631	$1.43	$3,762	Direct
Mar 25, 2025	TRVI Trevi Therapeutics, Inc.	Sale(S)	2,631	$6.60	$17,365	Direct
Mar 10, 2025	TRVI Trevi Therapeutics, Inc.	Award(A) Performance Stock Option (right to buy)	32,000	-	-	Direct
Feb 18, 2025	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	116,000	-	-	Direct

1-6 of 6 transactions

About SCIASCIA THOMAS

SCIASCIA THOMAS (SEC CIK 0001229946) files insider reports with the SEC as Chief Scientific Officer of Trevi Therapeutics, Inc. (TRVI).

Signal8 holds 5 ownership filings by SCIASCIA THOMAS, all Form 4s, filed between Feb 20, 2025 and Feb 20, 2026. Those filings report 6 transactions, from Feb 18, 2025 to Feb 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SCIASCIA THOMAS's filings is in NEW HAVEN, CT.

Recent filings by SCIASCIA THOMAS

Feb 19, 2026: Grant or award of TRVI derivative securities (Form 4, code A).
May 31, 2025: Grant or award of TRVI derivative securities (Form 4, code A).
Mar 25, 2025: Option exercise of TRVI shares (Form 4, code M).
Mar 25, 2025: Open-market sale of TRVI shares (Form 4, code S).
Mar 10, 2025: Grant or award of TRVI derivative securities (Form 4, code A).

Other insiders filing for Trevi Therapeutics, Inc. (TRVI)

Heffernan Michael Thomas, Director
Mathers Edward T, Director
Colangelo Dominick, Director
Meeker David P, Director
VANLENT ANNE, Director
Cassella James V, Chief Development Officer

How to read Form 4 transaction codes